Monte Rosa Therapeutics (GLUE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Monte Rosa Therapeutics

NasdaqGS•Healthcare•Biotechnology

$12.65-0.34(-0.03%)Pre-market

Market Cap

$1.23B

P/S

42.8x

P/B

2.5x

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability11/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Long cash runwayInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 28.8x5y range 15.3x – 61.9x

P/S · 42.8x5y range 2.1x – 403.7x

Currently above its 10-quarter median.

P/B · 2.5x5y range 1.2x – 5.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.23B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $28.73M
Q. Revenue: $8.97M
TTM EBITDA: $-171.07M
TTM Op. Income: $-181.85M
Q. Op. Income: $-49.13M
TTM Net Income: $-161.12M
Q. Net Income: $-43.40M
EPS: N/A
Shares Out.: $101.48M

$28.73M in TTM revenue declined 83.9% YoY, reaching $8.97M last quarter. TTM EBITDA of $-171.07M and TTM operating income of $-181.85M show growth is flowing through to the bottom line. However, net income is negative at $161.12M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -518.6%
Op. Margin: -547.8%
Net Margin: -483.9%

Op. margin of -547.8% is down 480.8% YoY — costs are rising relative to revenue. Net margin at -483.9% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 42.8x
P/B Ratio: 2.5x

P/S of 42.8x and P/B of 2.5x. P/S is high, meaning growth expectations are priced in. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $691.16M
Cash: $90.10M
Long-Term Debt: N/A
Book Value: $487.28M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-44.11M
TTM Free Cash Flow: $-32.08M
FCF Margin: -111.7%
FCF / Net Income: 0.2

TTM FCF of $-32.08M on $-44.11M in operating cash flow. The FCF / Net Income ratio of 0.2x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 234% — a weakening trend.